{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:04:51Z","timestamp":1791450291099,"version":"4.3.3"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T00:00:00Z","timestamp":1567728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2019.01990","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T08:05:46Z","timestamp":1567757146000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":201,"title":["Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders"],"prefix":"10.3389","volume":"10","author":[{"given":"Celine","family":"Kaegi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wuest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Schreiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs C.","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Vultaggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Matucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Boyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2019,9,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ."},{"key":"B2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/jech.52.6.377","article-title":"The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions","volume":"52","author":"Downs","year":"1998","journal-title":"J Epidemiol Commun Health."},{"key":"B3","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.anai.2017.07.032","article-title":"Clinical and biological response to rituximab treatment in 3 patients with acquired C1-inhibitor deficiency","volume":"119","author":"Busse","year":"2017","journal-title":"Ann Allergy Asthma Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1016\/j.amjmed.2005.09.018","article-title":"Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency","volume":"119","author":"Levi","year":"2006","journal-title":"Am J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1681\/ASN.2011040330","article-title":"Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy","volume":"23","author":"Berden","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1136\/annrheumdis-2014-206404","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial","volume":"74","author":"Jones","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B11","first-page":"S63","article-title":"Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients","volume":"29","author":"De Menthon","year":"2011","journal-title":"Clin Exp Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B15","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/bjh.12541","article-title":"A phase III randomized trial comparing glucocorticoid monotherapy versus glucocorticoid and rituximab in patients with autoimmune haemolytic anaemia","volume":"163","author":"Birgens","year":"2013","journal-title":"Br J Haematol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ajh.24570","article-title":"A randomized and double-blind controlled trial evaluating the safety and efficacy of rituximab for warm auto-immune hemolytic anemia in adults (the RAIHA study)","volume":"92","author":"Michel","year":"2016","journal-title":"Am J Hematol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1155\/2013\/512624","article-title":"Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy","volume":"27","author":"Burak","year":"2013","journal-title":"Can J Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study)","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int J Rheum Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1038\/jid.2013.236","article-title":"Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients","volume":"133","author":"Hall","year":"2013","journal-title":"J Invest Dermatol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1002\/ajh.21108","article-title":"Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series","volume":"83","author":"Bestawros","year":"2008","journal-title":"Am J Hematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"836","DOI":"10.7326\/0003-4819-147-12-200712180-00003","article-title":"Brief communication: rituximab in HIV-associated multicentric Castleman disease","volume":"147","author":"Bower","year":"2007","journal-title":"Ann Intern Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3350","DOI":"10.1200\/JCO.2007.10.6732","article-title":"Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB trial","volume":"25","author":"Gerard","year":"2007","journal-title":"J Clin Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0609.2005.00570.x","article-title":"Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab","volume":"76","author":"Ide","year":"2006","journal-title":"Eur J Haematol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1182\/blood-2003-03-0951","article-title":"Rituximab therapy for HIV-associated Castleman disease","volume":"102","author":"Marcelin","year":"2003","journal-title":"Blood."},{"key":"B25","first-page":"204","article-title":"Complete remission in 4 patients with human herpesvirus 8-associated multicentric Castleman disease using rituximab and liposomal doxorubicin, a novel chemotherapy combination","volume":"10","author":"Peker","year":"2012","journal-title":"Clin Adv Hematol Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1182\/blood-2007-08-106187","article-title":"Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease","volume":"110","author":"Powles","year":"2007","journal-title":"Blood."},{"key":"B27","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1182\/blood-2014-07-586800","article-title":"Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease","volume":"124","author":"Uldrick","year":"2014","journal-title":"Blood."},{"key":"B28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","article-title":"Pegylated interferon-alpha, ribavirin, rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study","volume":"116","author":"Dammacco","year":"2010","journal-title":"Blood."},{"key":"B29","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B30","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/art.34322","article-title":"A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis","volume":"64","author":"Sneller","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jaut.2015.07.012","article-title":"Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: long-term follow up data of a randomized controlled multicentre study","volume":"63","author":"Quartuccio","year":"2015","journal-title":"J Autoimmun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/qjmed\/hcr001","article-title":"Rituximab in anti-glomerular basement membrane disease","volume":"105","author":"Shah","year":"2012","journal-title":"QJM."},{"key":"B33","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves' orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","article-title":"Rituximab for IgG4-related disease: a prospective, open-label trial","volume":"74","author":"Carruthers","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/art.27435","article-title":"Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease","volume":"62","author":"Khosroshahi","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B38","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/MD.0b013e3182431ef6","article-title":"Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients","volume":"91","author":"Khosroshahi","year":"2012","journal-title":"Medicine."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1136\/annrheumdis-2015-207625","article-title":"Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years","volume":"74","author":"Yamamoto","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"21337","DOI":"10.18632\/oncotarget.25095","article-title":"IgG4-related kidney disease: the effects of a Rituximab-based immunosuppressive therapy","volume":"9","author":"Quattrocchio","year":"2018","journal-title":"Oncotarget."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1182\/blood-2011-08-374777","article-title":"A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia","volume":"119","author":"Arnold","year":"2012","journal-title":"Blood."},{"key":"B42","first-page":"2379","article-title":"Efficacy of standard dose rituximab for refractory idiopathic thrombocytopenic purpura in children","volume":"19","author":"Dai","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/S0140-6736(14)61495-1","article-title":"Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"385","author":"Ghanima","year":"2015","journal-title":"Lancet."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1182\/blood-2012-09-455691","article-title":"Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia","volume":"121","author":"Gudbrandsdottir","year":"2013","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/ajh.21512","article-title":"Repeated courses of rituximab in chronic ITP: three different regimens","volume":"84","author":"Hasan","year":"2009","journal-title":"Am J Hematol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12185-010-0753-z","article-title":"Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia","volume":"93","author":"Li","year":"2011","journal-title":"Int J Hematol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood."},{"key":"B48","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B49","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1136\/ard.2008.092106","article-title":"Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis","volume":"68","author":"Narvaez","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s10067-011-1720-7","article-title":"Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis","volume":"30","author":"Alexeeva","year":"2011","journal-title":"Clin Rheumatol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl J Med."},{"key":"B54","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann Neurol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/acn3.293","article-title":"Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis","volume":"3","author":"Komori","year":"2016","journal-title":"Ann Clin Transl Neurol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1002\/acn3.314","article-title":"Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up","volume":"3","author":"Anderson","year":"2016","journal-title":"Ann Clin Transl Neurol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology."},{"key":"B58","doi-asserted-by":"publisher","first-page":"201\u20132","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients","author":"Illa","year":"2008","journal-title":"J Neuroimmunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jneuroim.2016.07.009","article-title":"Therapeutic target of memory B cells depletion helps to tailor administration frequency of rituximab in myasthenia gravis","volume":"298","author":"Lebrun","year":"2016","journal-title":"J Neuroimmunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab","volume":"16","author":"Lebrun","year":"2009","journal-title":"Eur J Neurol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1600-0404.2010.01345.x","article-title":"Rituximab for severe myasthenia gravis\u2013experience from five patients","volume":"122","author":"Lindberg","year":"2010","journal-title":"Acta Neurol Scand."},{"key":"B62","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/CND.0b013e31819a8403","article-title":"Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review","volume":"10","author":"Nelson","year":"2009","journal-title":"J Clin Neuromuscul Dis."},{"key":"B63","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jns.2009.02.357","article-title":"Rituximab for myasthenia gravis: three case reports and review of the literature","volume":"280","author":"Stieglbauer","year":"2009","journal-title":"J Neurol Sci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/mus.23951","article-title":"Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis","volume":"49","author":"Sun","year":"2014","journal-title":"Muscle Nerve."},{"key":"B65","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/mus.26156","article-title":"Rituximab in refractory myasthenia gravis: extended prospective study results","volume":"58","author":"Beecher","year":"2018","journal-title":"Muscle Nerve."},{"key":"B66","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jneuroim.2017.05.021","article-title":"Responsiveness to low-dose rituximab in refractory generalized myasthenia gravis","volume":"311","author":"Jing","year":"2017","journal-title":"J Neuroimmunol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ki.2013.211","article-title":"Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome","volume":"84","author":"Ravani","year":"2013","journal-title":"Kidney Int."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1681\/ASN.2011080775","article-title":"Rituximab in children with resistant idiopathic nephrotic syndrome","volume":"23","author":"Magnasco","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","article-title":"Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial","volume":"6","author":"Ravani","year":"2011","journal-title":"Clin J Am Soc Nephrol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","article-title":"Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial","volume":"26","author":"Ravani","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","article-title":"Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial","volume":"172","author":"Basu","year":"2018","journal-title":"JAMA Pediatr."},{"key":"B73","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J Neurol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/bjd.12972","article-title":"Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study","volume":"170","author":"Kanwar","year":"2014","journal-title":"Br J Dermatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B77","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/ard.2009.119933","article-title":"Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate [Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)]","volume":"69","author":"Emery","year":"2010","journal-title":"Ann Rheum Dis."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum."},{"key":"B80","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/art.30194","article-title":"Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial","volume":"63","author":"Greenwald","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1136\/annrheumdis-2013-203480","article-title":"Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial","volume":"73","author":"Mariette","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3899\/jrheum.090442","article-title":"Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial","volume":"37","author":"Mease","year":"2010","journal-title":"J Rheumatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1136\/ard.2007.087023","article-title":"Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate","volume":"67","author":"Owczarczyk","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"B84","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/annrheumdis-2014-206015","article-title":"MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study","volume":"75","author":"Peterfy","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B85","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S0140-6736(16)00380-9","article-title":"Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial","volume":"388","author":"Porter","year":"2016","journal-title":"Lancet."},{"key":"B86","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12891-017-1673-3","article-title":"Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial","volume":"18","author":"Wijesinghe","year":"2017","journal-title":"BMC Musculoskelet Disord."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22340","article-title":"Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT","volume":"22","author":"Brown","year":"2018","journal-title":"Health Technol Assess."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/rheumatology\/kel358","article-title":"Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years","volume":"45","author":"Strand","year":"2006","journal-title":"Rheumatology."},{"key":"B89","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/annrheumdis-2011-200170","article-title":"Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE","volume":"71","author":"Tak","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B90","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/ard.2007.085787","article-title":"Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","article-title":"Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)","volume":"49","author":"Rubbert-Roth","year":"2010","journal-title":"Rheumatology."},{"key":"B93","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/ard.2010.137703","article-title":"Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial","volume":"70","author":"Tak","year":"2011","journal-title":"Ann Rheum Dis."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1136\/annrheumdis-2013-204544","article-title":"An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial","volume":"74","author":"Vital","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"B96","doi-asserted-by":"publisher","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sjogren syndrome with rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med."},{"key":"B97","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/annrheumdis-2017-212268","article-title":"Effect of rituximab on a salivary gland ultrasound score in primary Sjogren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy","volume":"77","author":"Fisher","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1136\/annrheumdis-2012-201897","article-title":"Rituximab in psoriatic arthritis: an exploratory evaluation","volume":"71","author":"Jimenez-Boj","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1002\/art.27383","article-title":"Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial","volume":"62","author":"Song","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B102","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/annrheumdis-2012-201926","article-title":"One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare","volume":"72","author":"Song","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B103","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum."},{"key":"B104","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B105","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s12013-014-0437-z","article-title":"Effect of rituximab on serum levels of anti-C1q and antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritis","volume":"72","author":"Zhang","year":"2015","journal-title":"Cell Biochem Biophys."},{"key":"B106","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S2173-5743(10)70058-7","article-title":"[Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study]","volume":"6","author":"Andrade-Ortega","year":"2010","journal-title":"Reumatol Clin."},{"key":"B107","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1136\/gut.2010.225482","article-title":"Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis","volume":"60","author":"Leiper","year":"2011","journal-title":"Gut."},{"key":"B109","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1093\/annonc\/mdv616","article-title":"Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis","volume":"27","author":"Fleury","year":"2016","journal-title":"Ann Oncol."},{"key":"B110","first-page":"112","article-title":"Malignancies after rituximab treatment: just coincidence or more?","volume":"16","author":"Aksoy","year":"2011","journal-title":"J BUON."},{"key":"B111","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/nrrheum.2014.123","article-title":"Adverse reactions to biologic agents and their medical management","volume":"10","author":"Boyman","year":"2014","journal-title":"Nat Rev Rheumatol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/all.12616","article-title":"EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders","volume":"70","author":"Boyman","year":"2015","journal-title":"Allergy."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01990\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T08:05:58Z","timestamp":1567757158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2019.01990\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,6]]},"references-count":112,"alternative-id":["10.3389\/fimmu.2019.01990"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2019.01990","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736673688.793582482","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,6]]},"article-number":"1990"}}